Metyos Raises €2.3mn to Revolutionize Chronic Kidney Disease Treatment

Paris-based startup Metyos has secured a €2.3mn pre-seed funding to develop biowearable technology aimed at improving the lives and health outcomes of chronic kidney disease patients. With CKD affecting 10% of the population and being the third fastest-growing cause of death worldwide, Metyos' biowearable sensor provides real-time readings on biomarkers related to CKD, enabling real-time monitoring and disease management for both patients and doctors. The startup plans to further develop its wearable technology and push it through clinical trials for FDA approval, with the goal of regulatory clearance by the end of 2025. The funding round was led by VC fund Cenitz and backed by KIMA Ventures, Advans Lab, and Bpifrance, among others. Metyos has garnered recognition, winning the Embedded Healthcare Trophy at the Association Embedded France awards in 2023, and being nominated as one of the top world health techpreneurs during the Healthcare Innovation World Cup.